[Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1]

We report our experience with concurrent chemoradiation for recurrent gastric cancers resistant to TS-1. From April 2000 to March 2003, we treated 10 consecutive patients with radiation and the concurrent single chemotherapy agent of TS-1 or CPT-11. Of the 10 patients, 3 (30%) had a complete response, 4 (40%) a partial response, and 3 (30%) stable disease, yielding an overall response rate of 70% (7/10). Three patients are alive and cancer-free, 5 patients died with cancers, and 2 patients are living with cancers as outpatients. The clinical benefit response was 90% (9/10). No patient has had either acute or late complication. Concurrent chemoradiation is feasible and seems to offer good results for recurrent gastric cancers resistant to TS-1.